<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407496</url>
  </required_header>
  <id_info>
    <org_study_id>TNI-NAT-1</org_study_id>
    <secondary_id>R43MH099709</secondary_id>
    <nct_id>NCT02407496</nct_id>
  </id_info>
  <brief_title>Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <acronym>NAT-I</acronym>
  <official_title>Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Think Now Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Think Now Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is develop a new assessment tool for Attention&#xD;
      Deficit-Hyperactivity Disorder (ADHD) and to then test its validity (i.e. ability to&#xD;
      discriminate between individuals with ADHD and healthy controls).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to develop a novel approach and software for analyzing&#xD;
      electroencephalography (EEG) data to identify biomarkers of ADHD. Then to test the ability of&#xD;
      this assessment tool to differentiate between adults with ADHD and healthy controls by&#xD;
      comparing the classification accuracy of the metrics from the new tool to the classification&#xD;
      accuracy of existing behavioral tests for ADHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NAT Slow Fluctuation Measure</measure>
    <time_frame>A single measurement is made for each individual at DAY 1 - the time of the brain wave test.</time_frame>
    <description>The NAT EEG test simultaneously generates 2 EEG values and 1 behavioral value that are used together as an assessment metric for ADHD. This is a one-time measure to assess its magnitude in ADHD vs Controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>ADHD</arm_group_label>
    <description>Adults with Attention Deficit Hyperactivity Disorder (ADHD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy individuals without ADHD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Behavioral assessment and NAT EEG tests</intervention_name>
    <description>Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.</description>
    <arm_group_label>ADHD</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Attention Deficit Hyperactivity Disorder (ADHD) from local clinics, clinicians.&#xD;
        ADHD community resources in the greater Los Angeles area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Specific inclusion criteria for ADHD are:&#xD;
&#xD;
               1. meet established DSM-5 criteria for ADHD predominately inattentive or combined&#xD;
                  subtype with clinically significant levels of impairment, diagnosed by structured&#xD;
                  clinical interview, the Mini International Neuropsychiatric Interview, and&#xD;
                  corroborating information&#xD;
&#xD;
               2. Clinical Global Impression-Severity (CGI-S) score â‰¥ 4 for ADHD&#xD;
&#xD;
               3. no lifetime history of DSM-5 bipolar disorder, psychotic disorder, pervasive&#xD;
                  developmental disorder, obsessive-compulsive disorder, substance abuse, or&#xD;
                  substance dependence (except nicotine) as assessed wit the MINI&#xD;
&#xD;
               4. able in the opinion of the investigator to complete all required study&#xD;
                  procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria for both groups are:&#xD;
&#xD;
               1. History of diagnosis of childhood disorder other than ADHD (e.g. autism,&#xD;
                  dyslexia)&#xD;
&#xD;
               2. history of any general medical condition likely to require chronic use of&#xD;
                  medication with identified CNS effects suspected to alter cognitive performance&#xD;
&#xD;
               3. history of seizure disorder, brain tumor, other major neurological disorder or&#xD;
                  head injury resulting in loss of consciousness&#xD;
&#xD;
               4. serious oxygen deprivation&#xD;
&#xD;
               5. current psychopathology requiring ongoing treatment with antipsychotic&#xD;
                  medications, mood stabilizers, benzodiazepines, or anticonvulsants&#xD;
&#xD;
               6. current untreated psychopathology which is rated to be primary in terms of&#xD;
                  severity (greater than ADHD severity)&#xD;
&#xD;
               7. current treatment with guanfacine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory V Simpson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Think Now, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark S Cohen, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Semel Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Think Now Incorporated</investigator_affiliation>
    <investigator_full_name>Gregory Simpson, Ph.D.</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

